[The phase II clinical trial of Seratia Marcescens Anticancer Vaccine (S311) for malignant pleural effusions].
BACKGROUND
To evaluate the effect and adverse reactions of Seratia Marcescens Anticancer Vaccine ( S311) in the treatment of malignant pleural effusions.


METHODS
0. 32 mg of S311 was administered into intracavity once a week, for successive three weeks, after draining off the pleural cavity completely by thoracocentesis or chest drainage.


RESULTS
Two hundred and forty-one patients with malignant effusions finished the arrangement of S311 therapy. The overall response rate was 92. 1%. The main adverse reactions were fever and pleuritic pain. Some patients had chill, dyspnea, nausea and vomiting. Liver dysfunction was observed in a few cases.


CONCLUSIONS
S311 is an effective drug for malignant pleural effusions.
Beijing Thoracic Tumor Research Institute, Beijing 101149, P . R . China.
Y
Y
Zhu
H
H
Shi
H
H
Qian
W
W
Huang
Z
Z
Hong
Y
Y
Zhang
N
N
Xu
L
L
Zhang
D
D
Liu
Z
Z
Tong
S
S
Li
L
L
Zhang
W
W
Zheng